Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …

Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …

Background Monalizumab is a first in class immune checkpoint inhibitor targeting Natural
Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of …

6516 Background: Monalizumab is a first-in-class immune checkpoint inhibitor targeting
Natural Killer Group 2A (NKG2A), which is expressed on subsets of Natural Killer (NK), gd T …

Background Second-line treatment options for advanced head and neck squamous cell
carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety …

TPS6084 Background: Prognosis of patients with recurrent or metastatic head and neck
squamous cell carcinoma (R/M HNSCC) is poor, with limited treatment options and survival …

Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

6012 Background: The PD-1 pathway is a key mechanism by which R/M HNSCC tumors
evade immune surveillance. Pembrolizumab (pembro), an anti–PD-1 antibody, showed …

6000 Background: KEYNOTE-048 is a phase 3 study of P or P+ chemo (C) vs EXTREME (E)
as 1L therapy for R/M HNSCC (NCT02358031). At the second interim analysis (IA2), P …

Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent
metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial …